<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03019198</url>
  </required_header>
  <id_info>
    <org_study_id>06554913.0.0000.5273</org_study_id>
    <nct_id>NCT03019198</nct_id>
  </id_info>
  <brief_title>TRANEXAMIC ACID IN PATIENTS UNDERGOING TOTAL HIP ARTHROPLASTY IN A BRAZILIAN REFERENCE ORTHOPEDIC CENTER: A RANDOMIZED CONTROLLED TRIAL</brief_title>
  <official_title>TRANEXAMIC ACID IN PATIENTS UNDERGOING TOTAL HIP ARTHROPLASTY IN A BRAZILIAN REFERENCE ORTHOPEDIC CENTER: A RANDOMIZED CONTROLLED TRIAL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Traumatologia e Ortopedia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Traumatologia e Ortopedia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to analyze the efficacy of intravenous tranexamic acid (TXA) in patients
      undergoing total hip arthroplasty (THA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a prospective, experimental, randomized, controlled study of 308 consecutive
      patients who underwent primary THA from December 2013 to March 2014. 256 volunteers remained
      in the study, 128 were treated 15 mg/kg intravenous bolus of TXA and 128 did not receive the
      medication. Participants were followed up at 3 weeks, 3 months, 6 months, 1 year, and then
      annually after surgery.

      The use of TXA resulted in lesser reduction in hemoglobin and hematocrit levels, reduced
      blood loss, blood transfusion rate, volume of blood products, and stay length even in risk
      factor patients.

      TXA protects risk factor patients against intra and postoperative bleeding and reduces
      transfusion rates.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin drop</measure>
    <time_frame>24 hours post operative</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematocrit drop</measure>
    <time_frame>24 hours post operative</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood transfusion rate</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Operative blood loss</measure>
    <time_frame>24 hours post operative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay in hospital</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic adverse events</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic efects</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">256</enrollment>
  <condition>Blood Loss, Surgical</condition>
  <condition>Tranexamic Acid Adverse Reaction</condition>
  <condition>Hip Replacement</condition>
  <arm_group>
    <arm_group_label>TXA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Performed an intravenous bolus administration of 15 mg/kg of TXA to the volunteers after the end of the anesthesia and 15 minutes prior to skin incision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group underwent the same procedures of the TXA group, excepting the preoperative administration of the medication.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid Injectable Solution</intervention_name>
    <description>Intravenous 15 mg per kilogram tranexamic acid</description>
    <arm_group_label>TXA</arm_group_label>
    <other_name>Lysteda</other_name>
    <other_name>Transamin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - Concentrate</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive patients who need total hip replacement were included in the initial
             sample. There was no age limit or restriction regarding gender for admission to the
             study.

        Exclusion Criteria:

          -  Patients who underwent previous surgery in the same joint, evidence of joint
             infection, congenital or acquired coagulopathies, active intravascular coagulation,
             acute occlusive vasculopathy, hypersensitivity to TXA, chronic use of oral and steroid
             anticoagulants, history of severe or moderate allergy to plasma transfusion, chronic
             heart disease, malignant neoplasms and autoimmune diseases, patients who needed bone
             graft or underwent hip arthroplasty revision surgeries, and who did not consent to
             participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto Nacional de Traumatologia e Ortopedia</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20940070</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2017</study_first_submitted>
  <study_first_submitted_qc>January 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2017</study_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Traumatologia e Ortopedia</investigator_affiliation>
    <investigator_full_name>Osamu de Sandes Kimura</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Tranexamic Acid</keyword>
  <keyword>Blood loss</keyword>
  <keyword>Tranfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

